Scientific excellence is not an end in itself, but is a crucial tool for efficient translation of new ideas into viable solutions.

Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto P, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, Gruijl T de, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F et al. (2011)

Defining the critical hurdles in cancer immunotherapy.

J Transl Med 2011, 9:214.

van der Burg, S. H., Kalos M, Gouttefangeas C, Janetzki S, Ottensmeier C, Welters, M. J. P., Romero P, Britten CM, Hoos A. (2011)

Harmonization of Immune Biomarker Assays for Clinical Studies.

Science Translational Medicine 2011, 3:108ps44.

Hobohm K, Seppmann T, Britten CM, Hoff H. (2011)

Ninth annual meeting of the Association for Cancer Immunotherapy (CIMT 2011), May 25-27, 2011, Mainz, Germany.

Cancer immunology, immunotherapy: CII 2012, 61:137-143.

Hoos A, Britten CM, Huber C, O’Donnell-Tormey J. (2011)

A methodological framework to enhance the clinical success of cancer immunotherapy.

Nat Biotechnol 2011, 29:867-870.

Cancer Res. 2011 Oct 1;71(19):6132-42.

FLT3 ligand Enhances the Cancer Therapeutic Potency of Naked RNA Vaccines.

Kreiter, S., Diken, M., Selmi, A., Diekmann, J., Attig, S., Husemann, Y., Koslowski, M., Huber, C., Türeci, Ö., and Sahin, U. (2011)

Kreiter S, Diken M, Selmi A, Diekmann J, Attig S, Hüsemann Y, Koslowski M, Huber C, Türeci Ö, Sahin U. (2011)

FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines. Cancer research 2011, 71.

Cancer research 2011, 71:6132-6142.

Bedognetti D, Balwit JM, Wang E, Disis ML, Britten CM, Delogu LG, Tomei S, Fox BA, Gajewski TF, Marincola FM, Butterfield LH. (2011)

SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: Online resources and useful tools – a compass in the land of biomarker discovery.

J Transl Med 2011, 9:155.

Moodie Z, Price L, Janetzki S, Britten CM. (2011)

Response determination criteria for ELISPOT: toward a standard that can be applied across laboratories.

Methods in molecular biology (Clifton, N.J.) 2012, 792:185-196.

Renard BY, Löwer M, Kühne Y, Reimer U, Rothermel A, Türeci O, Castle JC, Sahin U. (2011)

rapmad: Robust analysis of peptide microarray data.

BMC bioinformatics 2011, 12:324.

Türeci O, Koslowski M, Helftenbein G, Castle J, Rohde C, Dhaene K, Seitz G, Sahin U. (2011)

Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals.

Gene 2011, 481:83-92.

Attig S, Price L, Janetzki S, Kalos M, Pride M, McNeil L, Clay T, Yuan J, Odunsi K, Hoos A, Romero P, Britten CM. (2011)

A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols.

Journal of translational medicine 2011, 9:108.

Castle JC. (2011)

SNPs occur in regions with less genomic sequence conservation.

PloS one 2011, 6:e20660.

Kreiter S, Diken M, Selmi A, Türeci Ö, Sahin U. (2011)

Tumor vaccination using messenger RNA: prospects of a future therapy.

Current opinion in immunology 2011, 23:399-406.

Schneider S, Carra G, Sahin U, Hoy B, Rieder G, Wessler S. (2011)

Complex cellular responses of Helicobacter pylori-colonized gastric adenocarcinoma cells.

Infection and immunity 2011, 79:2362-2371.

Butterfield LH, Palucka AK, Britten CM, Dhodapkar MV, Hakansson L, Janetzki S, Kawakami Y, Kleen T, Lee PP, Maccalli C, Maecker HT, Maino VC, Maio M, Malyguine A, Masucci G, Pawelec G, Potter DM, Rivoltini L, Salazar LG, Schendel DJ, Slingluff CL, Song W, Stroncek DF, Tahara H, Thurin M, Trinchieri G, van der Burg, S. H., Whiteside TL, Wigginton JM, Marincola F et al. (2011)

Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers.

Clinical Cancer Research 2011, 17:3064-3076.

Diken, M., Kreiter, S., Selmi, A., Britten, C.M., Huber, C., Türeci, Ö., and Sahin, U. (2011)

Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation.

Gene Ther. 2011 Jul;18(7):702-8.

Klamp T, Schumacher J, Huber G, Kühne C, Meissner U, Selmi A, Hiller T, Kreiter S, Markl J, Türeci Ö, Sahin U. (2011)

Highly specific auto-antibodies against claudin-18 isoform 2 induced by a chimeric HBcAg virus-like particle vaccine kill tumor cells and inhibit the growth of lung metastases.

Cancer research 2011, 71:516-527.

Kuhn AN, Diken M, Kreiter S, Vallazza B, Türeci Ö, Sahin U. (2011)

Determinants of intracellular RNA pharmacokinetics: Implications for RNA-based immunotherapeutics.

RNA biology 2011, 8:35-43.